1 04, 2019

Delayed-Onset Toxicity In An Adolescent Case Following Attempted Suicide With An Overdose Of Paliperidone Intake

By |2019-04-01T18:18:30-07:00April 1st, 2019|Articles In Press|0 Comments

Ferhat Yaylacı, Önder Küçük, and Handan Özek Erkuran ABSTRACT Paliperidone is a relatively novel atypical antipsychotic drug that is currently used to treat schizophrenia in adolescents and adults.  The drug was generated by combining the active metabolite of risperidone, 9- hydroxyrisperidone, with osmotic controlled- release oral administration system (OROS) technology. [...]

1 04, 2019

Identifying Predictors of Primary Adherence to Second Generation Long-Acting Injectable Antipsychotics Following Discharge from an Acute Inpatient Psychiatry Unit

By |2019-04-01T18:16:49-07:00April 1st, 2019|Articles In Press|0 Comments

Jenna L. Gilbert, Leigh Anne Nelson, Pharm.D., BCPP, Carrie R. Kriz, MS, Yifei Liu, B.S. Pharm, Ph.D., Courtney A. Iuppa, Pharm.D., BCPP, Lauren A. Diefenderfer, Pharm.D., BCPP, Ellie S.R. Elliott, Pharm.D., BCPP, and Roger W. Sommi, Pharm.D., BCPP, FCCP Abstract Describe primary adherence and medication persistence to second generation long-acting injectable (LAI) antipsychotics following an inpatient psychiatry [...]

28 03, 2019

Study Shows the Need for Psychiatric Care to be Integrated into Cancer Treatment

By |2019-03-28T14:15:40-07:00March 28th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Patients with prostate, bladder or kidney cancers are at greater risk of dying if they have had psychiatric care prior to the cancer treatment. In addition, patients with these cancers show greater suicide risk than the general population, even once the data is corrected for previous psychiatric care. These are [...]

21 03, 2019

Biogen, Eisai discontinue Alzheimer’s trials

By |2019-03-21T18:28:53-07:00March 21st, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Biogen and Eisai have announced that they are discontinuing the ENGAGE and EMERGE trials, which were designed to test the efficacy and safety of aducanumab in patients with mild cognitive impairment caused by Alzheimer’s disease and mild Alzheimer’s disease dementia. The phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group trials were [...]

20 03, 2019

FDA Approves Brexanolone, First Drug for Postpartum Depression

By |2019-03-20T11:48:10-07:00March 20th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The US Food and Drug Administration (FDA) has approved brexanolone intravenous infusion (Zulresso, Sage Therapeutics), the first-ever drug indicated for the treatment of postpartum depression. The drug is administered under medical supervision as a continuous infusion over a total of 60 hours (2.5 days), according to the FDA. Postpartum depression can [...]

6 03, 2019

Alzheimer Drug Plus SSRI May Improve Depression/Cognition

By |2019-03-06T13:40:42-07:00March 6th, 2019|Brief Bulletins from the Field, Uncategorized, We Know Psychiatry|0 Comments

Adding the Alzheimer drug memantine (Namenda, Allergan) to treatment with a selective serotonin reuptake inhibitor may improve depressive symptoms, executive function, and other outcomes in older patients with both depression and cognitive complaints, new research suggests. The findings were presented at the American Association of Geriatric Psychiatry (AAGP) 2019. In a [...]

6 03, 2019

FDA Approves Intranasal Ketamine for Major Depressive Disorder

By |2019-03-06T08:05:04-07:00March 6th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The Food and Drug Administration yesterday approved an intranasal form of esketamine for treatment-resistant depression in adults who have failed at least two oral antidepressants of different classes. The spray, from Janssen Pharmaceutical (Spravato) is available in tamper-resistant prepackaged units of one, two, or three devices to deliver the prescribed doses [...]

15 02, 2019

Improved efficacy of pregabalin by restoring plasma vitamin D levels in migraine: a case report.

By |2019-02-15T12:23:46-07:00February 15th, 2019|Articles In Press|0 Comments

Antonio Siniscalchi, MD; Piergiorgio Lochner; Erika Cione, PhD; Adelia Michniewicz, Biotechnologist; Vincenzo Guidetti, MD; Luca Gallelli, MD Abstract Migraine appears to be the most common neurological syndrome in primary care. Pain in migraine is mediated by the release of inflammatory mediators at the level of nerves and blood vessels. The antioxidant and neuroprotective effects of [...]

15 02, 2019

Successful Resolution of Prominent Somatic Delusions following Bi-temporal Electroconvulsive Therapy in a patient with Treatment- Resistant Schizoaffective disorder

By |2019-02-15T12:07:40-07:00February 15th, 2019|Articles In Press|0 Comments

Joshua L. Cohen, PhD; My-Hanh Thi Vu, MD; Mirza Adam Beg, BS; Soumya Sivaraman, MD; and Badari Birur, MD Abstract Somatic delusions occur in a variety of psychiatric disorders including schizophrenia, major depressive disorder, and bipolar disorder. Somatization is associated with lower quality of life and greater risk for suicide. Treatment [...]

18 01, 2019

Combination of Ketamine and Naltrexone Shows Promise for Addiction Treatments and Depression

By |2019-01-18T11:06:43-07:00January 18th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

  A preliminary study of five patients suffering from both depression and substance abuse disorders suggest that isn’t the case. The study was published Jan. 9 in the journal JAMA Psychiatry. Substance abuse and depression are common in many patients, and efforts to treat both conditions simultaneously have had limited [...]